SunWay Biotech Co

SunWay Biotech Co FCF/Debt

The Free Cash Flow to Debt Ratio of SunWay Biotech Co (1271.TWO) as of Oct 20, 2026 is 29.07 %. In the previous year, Free Cash Flow to Debt Ratio was 13.30 % — a change of 118.52% (higher).

FCF/Debt

29.07 %

YoY

118.52%

Last updated:

Free Cash Flow to Debt Ratio of SunWay Biotech Co is 2025 29.07 % . Free Cash Flow to Debt Ratio of SunWay Biotech Co was 2024 13.30 % . It decreases by 118.52% higher compared to the previous year.

The SunWay Biotech Co FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2020
1,062.88 TWD
Jan 1, 2021
729.77 TWD
Jan 1, 2022
56.06 TWD
Jan 1, 2023
3.21 TWD
Jan 1, 2024
13.30 TWD
Jan 1, 2025
29.07 TWD
The SunWay Biotech Co FCF/Debt history
YEARFCF/DebtYoY
29.07 %+118.52%
13.30 %+314.38%
3.21 %-94.27%
56.06 %-92.32%
729.77 %-31.34%
1,062.88 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SunWay Biotech Co Stock analysis

What does SunWay Biotech Co do? SunWay Biotech Co., Ltd. generates revenue through the research, development, manufacture, and sale of red yeast health food products. The company's main products include Lactobacillus paracasei subsp. paracasei NTU 101 and Monascus purpureus NTU 568, which target digestive health, bacterial ecology regulation, immunity, and allergy management. These products are sold in both domestic and overseas markets, catering to consumers seeking natural health solutions. The firm focuses on health food segments where digestive and immune support are key consumer needs. The company's product portfolio emphasizes specific strains like Lactobacillus paracasei subsp. paracasei NTU 101 and Monascus purpureus NTU 568, which are marketed for their functional benefits in digestion and immune regulation. These health foods are distributed across domestic and international channels, targeting health-conscious consumers who prioritize natural remedies. SunWay Biotech leverages its research-driven approach to position these products in the health food market. SunWay Biotech Co., Ltd. operates within the health food industry, focusing on products that address digestive and immune health through natural ingredients. Its offerings are designed to improve bacterial ecology in the digestive tract and regulate immunity and allergies, appealing to a segment of consumers interested in preventive health solutions. The company's domestic and overseas market strategy ensures broad reach for its specialized health food products. SunWay Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SunWay Biotech Co stock

Free Cash Flow to Debt Ratio of SunWay Biotech Co is 29.07 % in 2025.

Free Cash Flow to Debt Ratio of SunWay Biotech Co changed from 13.30 % to 29.07 %, representing a 118.52% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio SunWay Biotech Co since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's SunWay Biotech Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — SunWay Biotech Co

All Key Metrics — SunWay Biotech Co